DAFTAR PUSTAKA
A Chariri dan I Ghozali. 2001. Teori Akuntansi (Edisi 1). Badan Penerbit UNDIP,
Semarang
Agnes Sawir. 2003. Analisis Kinerja Keuangan dan Perencanaan Keuangan
Perusahaan, PT. Gramedia Pustaka Utama, Jakarta
Arthur J.Keown, John D. Martin. 2010. Manajemen Keuangan: Prinsip dan
Penerapan (Jilid 2). Indeks. Jakarta
Bambang Riyanto. 2001. Dasar-dasar Pembelanjaan Perusahaan, BPFEYogyakarta, Yogyakarta
Darsono dan Ashari. 2005. Pedoman Praktis Memahami Laporan Keuangan,
Penerbit Andi, Yogyakarta
Djarwanto. 2010. Pokok-pokok Analisa Laporan Keuangan (Edisi 2). BPFEYogyakarta, Yogyakarta
Gill, James O dan Chatton Moira. 2008. Memahami Laporan Keuangan, PPM,
Jakarta
Kasmir. 2008. Analisis Laporan Keuangan, PT Raja Grafindo Persada, Jakarta.
Martono dan Agus Harjito. 2008. Manajemen Keuangan Edisi 1, Ekonesia,
Yogyakarta
Myer N. John. 1994. Analisa Neraca Rugi-Laba. Rineka Cipta. Bandung
R.Agus Sartono. 2001. Manajemen Keuangan Teori dan Aplikasi, BPFEYogyakarta, Yogyakarta
142
http://digilib.mercubuana.ac.id/
143
S. Munawir. 2010. Analisa Laporan Keuangan Edisi 4, Liberti, Yogyakarta
Sofyan Syafri Harahap. 2002. Analisa Kritis Atas Laporan Keuangan, Binarupa,
Jakarta
Sundjaja Ridwan dan Inge Barlian. 2001. Manajemen Keuangan Satu (Edisi 4),
PT. Prenhallindo, Jakarta
Sutrisno. 2005. Manajemen Keuangan: Teori, Konsep dan Aplikasi. Ekonisia FE
UII. Yogyakarta
www.darya-varia.com
www.idx.co.id
www.indofarma.co.id
http://digilib.mercubuana.ac.id/
PT Tempo Scan Pacific Tbk.
Head Office
Factories
Business
Company Status
Tempo Scan Pacific Tower 16th Floor
Jl. HR. Rasuna Said Kav. 3-4, Jakarta 12950
Phone (021) 2921-8888
Fax (021) 2920-9999
Email: investorrelation@thetempogroup.com
Website: www.thetempogroup.com
- EJIP Industrial Park Plot I G
Lemahabang, Bekasi 17550
Phone (021) 897-1553, 897-5173
Fax (021) 897-1563
- EJIP Industrial Park Plot I H
Lemahabang, Bekasi 17550
Phone (021) 897-0801, 897-0802
Fax (021) 897-0764
Pharmaceuticals
PMDN
Pharmaceuticals
Summary of Financial Statement
(Million Rupiah)
2011
2012
2013
Total Assets
Current Assets
of which
Cash and cash equivalents
Trade receivables
Inventories
Non-Current Assets
of which
Fixed Assets-Net
Deffered Tax Assets-Net
Investments
Other Assets
4,250,374
3,121,980
4,632,985
3,393,778
5,407,958
3,991,116
1,608,819
599,337
726,343
1,128,395
1,651,451
745,771
764,579
1,239,207
1,792,222
808,788
1,000,694
1,416,842
886,135
36,605
20,101
154,922
1,000,822
40,322
18,550
137,792
1,203,852
36,028
15,767
136,605
Liabilities
Current Liabilities
of which
Bank loans
Trade payables
Taxes payable
Non-Current Liabilities
1,204,439
1,046,406
1,279,829
1,097,135
1,545,006
1,347,466
139,740
574,346
43,704
158,032
93,838
628,807
56,703
182,694
184,500
745,323
34,136
197,540
Financial Performance: The Company booked net income
amounted IDR674 billion in 2013, higher than last year income
worth IDR643 billion.
Brief History: TSP has been a certified GMP pharmaceutical manufacturer since 1990 with certification for 11 kinds of
dosage forms. To date, the company has already produced and
marketed 105 items for distribution domestically and 43 items
for export.
TSP’s production activities are carried out at its 11,622
sq metres plant in Cawang, East Jakarta. Its factory was recently
upgraded and it has a work force of 945.
Tablet capacity is by far the largest compared to the capsule and liquid lines. The table line is currently running at 90%
utilisation based on one extended shift per day. The table capacity is primarily devoted to the production of the Bode lines.
Total tablet production is approximately two billion units
per year, while capsules are around 110 million units and liquid,
38 billion bottles.
The majority of its capsule machinery is for the production of Hemaviton. TSP’s strength lies in its OTC products with
major brands Brodex, Brodexin, and Hemaviton, collectively,
contributing approximately 70% of the consolidated pharmaceutical revenue.
These products reportedly generate very high gross margins estimated to be around 60%. Neo-Rheumacyl the largest
single product contributor to the ethical product line, contribute around 16% of the consolidated pharmaceutical revenue.
Advertising and promotional activities are very important for
successfully marketing OTC products and maintaining brand
royalty. TSP allocates approximately 20% of its OTC revenue
for this purpose. Although the percentage may seem slightly
lower than those of its competitors, this is because most of its
OTC products are already very well known in Indonesia.
Shareholders' Equity
Paid-up capital
Paid-up capital
in excess of par value
Revaluation of fixed assets
Retained earnings
3,045,935
225,000
3,353,156
225,000
3,862,952
225,000
124,457
n.a
2,696,478
124,457
n.a
3,003,699
397,349
n.a
3,240,603
Net Sales
Cost of Goods Sold
Gross Profit
Operating Expenses
Operating Profit
Other Income (Expenses)
Profit (loss) before Taxes
Comprehensive Profit (loss)
5,780,664
3,580,621
2,200,043
1,542,254
657,788
82,312
740,100
585,309
6,630,810
4,142,489
2,488,321
1,786,514
701,807
110,573
812,380
643,568
6,854,889
4,135,087
2,719,803
2,071,818
647,985
181,951
829,935
674,147
Per Share Data (Rp)
Earnings per Share
Equity per Share
Dividend per Share
Closing Price
130
677
75
2,550
143
745
75
3,725
150
858
n.a
3,250
Financial Ratios
PER (x)
PBV (x)
Dividend Payout (%)
Dividend Yield (%)
19.61
3.77
0.58
0.03
26.05
5.00
0.52
0.02
21.69
3.79
n.a
n.a
Current Ratio (x)
Debt to Equity (x)
Leverage Ratio (x)
Gross Profit Margin (x)
Operating Profit Margin (x)
Net Profit Margin (x)
Inventory Turnover (x)
Total Assets Turnover (x)
ROI (%)
ROE (%)
2.98
0.40
0.28
0.38
0.11
0.10
4.93
1.36
13.77
19.22
3.09
0.38
0.28
0.38
0.11
0.10
5.42
1.43
13.89
19.19
2.96
0.40
0.29
0.40
0.09
0.10
4.13
1.27
12.47
17.45
Shareholders
PT Bogamulia Nagadi
Public
PER = 13,76x ; PBV = 2,89x (June 2014)
Financial Year: December 31
Public Accountant: Tanubrata Sutanto Fahmi & Rekan
77.34%
22.66%
498
Indonesian Capital Market Directory 2014
http://digilib.mercubuana.ac.id/
PT Tempo Scan Pacific Tbk.
Pharmaceuticals
Board of Commissioners
President Commissioner
Dian Paramita Tamzil
Commissioners Kustantinah, Olga Asihjati Adjiputro Wijaya,
Julian Aldrin Pasha
Board of Directors
President Director Handojo Selamet Muljadi
Vice President Directors Diana Wirawan, Dewi Murni Sukahar
Directors Dondi Sapto Margono, Liza Prasodjo,
Irawati Sutanto, Phillips Gunawan, Hartaty Susanto,
Aviaska Diah Respati Herlambang
Suryadi Nagawiguna, Johanes Ivan Pradjanata
Number of Employees 5,900
No
Type of Listing
1
2
3
4
5
First Issue
Company Listing
Stock Split
Right Issue
Stock Split
Listing Date
Trading Date
Number of Shares
per Listing
17-Jun-94
17-Jun-94
13-Nov-95
09-Feb-98
14-Sep-06
17-Jun-94
24-Jan-95
13-Nov-95
09-Feb-98
14-Sep-06
17,500,000
57,500,000
75,000,000
300,000,000
4,050,000,000
Total Listed
Shares
17,500,000
75,000,000
150,000,000
450,000,000
4,500,000,000
Underwriter
PT DBS Securities
Stock Price, Frequency, Trading Days, Number and Value of Shares Traded and Market Capitalization
Month
January-13
February-13
March-13
April-13
May-13
June-13
July-13
August-13
September-13
October-13
November-13
December-13
January-14
February-14
March-14
April-14
May-14
June-14
Stock Price
High
Low
(Rp)
(Rp)
3,725
3,425
3,550
3,100
3,850
3,000
3,850
3,250
4,950
3,325
4,600
3,750
4,225
3,550
4,025
3,250
3,800
3,050
3,900
3,550
3,800
2,850
3,375
3,050
3,200
2,850
3,370
2,745
3,450
3,020
3,250
2,865
2,900
2,700
3,015
2,710
Shares Traded
Close
Volume
Value
(Rp) (Thousand Shares)
(Rp Million)
3,550
28,269.00
99,577.00
3,225
24,084.00
79,779.00
3,850
47,156.00
151,844.00
3,400
43,238.00
151,395.00
4,750
199,513.00
771,890.00
4,150
45,968.00
196,364.00
4,100
12,851.00
50,922.00
3,650
8,105.00
29,405.00
3,800
10,187.00
33,552.00
3,900
34,784.00
119,516.00
3,325
39,277.00
129,023.00
3,250
32,081.00
100,510.00
2,900
13,733.00
41,168.00
3,340
41,227.00
124,974.00
3,170
29,825.00
95,043.00
2,900
34,939.00
103,130.00
2,770
53,608.00
152,574.00
3,000
48,222.00
141,984.00
Trading
Listed
Market
Frequency
Day
Shares
1,206
1,310
2,644
1,783
4,855
2,780
1,400
1,046
2,580
1,723
4,529
1,630
4,496
5,004
3,689
5,803
5,306
3,148
21
20
19
22
22
19
23
17
21
21
20
19
20
20
20
20
18
21
4,500,000,000
4,500,000,000
4,500,000,000
4,500,000,000
4,500,000,000
4,500,000,000
4,500,000,000
4,500,000,000
4,500,000,000
4,500,000,000
4,500,000,000
4,500,000,000
4,500,000,000
4,500,000,000
4,500,000,000
4,500,000,000
4,500,000,000
4,500,000,000
Capitalization
(Rp Million)
15,975,000.00
14,512,500.00
17,325,000.00
15,300,000.00
21,375,000.00
18,675,000.00
18,450,000.00
16,425,000.00
17,100,000.00
17,550,000.00
14,962,500.00
14,625,000.00
13,050,000.00
15,030,000.00
14,265,000.00
13,050,000.00
12,465,000.00
13,500,000.00
Stock Price and Traded Chart
Stock Price (Rp)
Thousand Shares
5,000
10,000
4,500
9,000
4,000
8,000
3,500
7,000
3,000
6,000
2,500
5,000
2,000
4,000
1,500
3,000
1,000
2,000
500
1,000
-
Jan-13
Mar-13
May-13
Jul-13
Sep-13
Nov-13
Institute for Economic and Financial Research
http://digilib.mercubuana.ac.id/
Jan-14
Mar-14
May-14
499
PT Darya-Varia Laboratoria Tbk.
Head Office
Factory
Business
Company Status
Talavera Office Park 8th -10th Floor
Jl. Letjend. T.B. Simatupang No. 22-26
Jakarta 12430
Phone (021) 7592-4500
Fax (021) 7592-4501
E-mail: info@darya-varia.com
Website: http://www.darya-varia.com
Jl. Mercedes Benz No. 105, Desa Cicadas
Gunung Putri, Citeureup, Bogor, Jawa Barat
Phone (021) 867-0448, 867-1038
Fax (021) 867-2758
Pharmaceuticals
PMA
Financial Performance: In 2013 the Company booked
net income at IDR125 billion, decreased from IDR148 billion
booked in 2012.
Brief History: Founded in 1976 by Drs. Wim Kalona, PT
Darya-Varia Laboratoria Tbk today operates two manufacturing facilities after closing two other plants in 1998 as part of the
Group re-structuring.
In end of December 2001, Far East Drug, an affiliated of
Unilab Group of Philippines purchased DVL Investment Limited
(DVLIL) which owns 89.5% of the total shares issued by DaryaVaria, from First Pacific Group, Hong Kong.
In July 2006, DVLIL and Far East Drug (BVI) Ltd. transferred their Darya-Varia shares to Blue Sphere Singapore Pte.
Ltd. that is now the majority shareholder of Darya-Varia, which
owns 92.7% shares of the Company.
Shareholders
Blue Sphere Singapore Pte., Ltd
Public
92.66%
7.34%
Pharmaceuticals
Summary of Financial Statement
(Million Rupiah)
2011
2012
2013
Total Assets
Current Assets
of which
Cash and cash equivalents
Trade receivables
Inventories
Non-Current Assets
of which
Fixed Assets-Net
Deffered Tax Assets-Net
Investments
Other Assets
922,945
696,925
1,074,691
826,343
1,190,054
913,984
256,481
311,526
118,444
226,020
292,912
390,003
132,823
248,349
316,701
377,105
206,682
276,070
194,532
14,736
n.a.
2,982
218,295
13,770
n.a.
2,175
243,055
16,841
n.a.
2,419
Liabilities
Current Liabilities
of which
Trade payables
Taxes payable
Accrued Expenses
Non-Current Liabilities
195,028
142,424
233,145
191,718
275,351
215,473
29,288
16,909
65,554
52,604
34,553
13,645
105,559
41,427
52,197
7,536
111,038
59,878
Shareholders' Equity
Paid-up capital
Paid-up capital
in excess of par value
Revaluation of fixed assets
Retained earnings (accumulated loss)
727,917
280,000
841,546
280,000
914,703
280,000
77,828
n.a
370,089
77,828
n.a
483,718
77,828
n.a
556,874
Net Sales
Cost of Goods Sold
Gross Profit
Operating Expenses
Operating Profit
Other Income (Expenses)
Profit (loss) before Taxes
Comprehensive Profit (loss)
899,632
349,019
550,613
390,435
160,178
6,147
166,325
120,915
1,087,380
436,270
651,110
454,944
196,166
8,311
204,477
148,909
1,101,684
441,028
660,656
493,577
167,079
8,678
175,757
125,796
Per Share Data (Rp)
Earnings (Loss) per Share
Equity per Share
Dividend per Share
Closing Price
108
650
n.a
1,150
133
751
35
1,690
112
817
22
2,200
Financial Ratios
PER (x)
PBV (x)
Dividend Payout (%)
Dividend Yield (%)
10.65
1.77
n.a
n.a
12.71
2.25
0.26
0.02
19.59
2.69
0.20
0.01
Current Ratio (x)
Debt to Equity (x)
Leverage Ratio (x)
Gross Profit Margin (x)
Operating Profit Margin (x)
Net Profit Margin (x)
Inventory Turnover (x)
Total Assets Turnover (x)
ROI (%)
ROE (%)
4.89
0.27
0.21
0.61
0.18
0.13
2.95
0.97
13.10
16.61
4.31
0.28
0.22
0.60
0.18
0.14
3.28
1.01
13.86
17.69
4.24
0.30
0.23
0.60
0.15
0.11
2.13
0.93
10.57
13.75
PER = 17,28x ; PBV = 1,65x (June 2014)
Financial Year: December 31
Public Accountant: Purwantono, Suherman & Surja
480
Indonesian Capital Market Directory 2014
http://digilib.mercubuana.ac.id/
PT Darya-Varia Laboratoria Tbk.
Pharmaceuticals
Board of Commissioners
President Commissioner
Jocelyn Campos Hess
Vice President Commissioner Sunarto Prawirosujanto
Commissioners Clinton Andrew Campos Hess,
Mariano John L. Tan, Jr.,
Laksamana Madya (Purn.) Soedibyo Rahardjo,
Sonny Kalona, Manual P. Engwa
Board of Directors
President Director Charles Robert Bernabe Davis
Directors Carlos O. Nava, Marlia Hayati Gustam,
Yustina Endang Setyowati,
Angelito Celso C. Racho, Jr.,
Farida Oktaria Chalid, Bhanuwati Citarasmi
Number of Employees 1,512
No
Type of Listing
1
2
3
4
5
6
7
8
First Issue
Company Listing
Conversion
Stock Split
Bonus Shares
Right Issue
Right Issue
Stock Split
Listing Date
Trading Date
Number of Shares
per Listing
11-Nov-94
11-Nov-94
21-Nov-94
12-Oct-95
26-Oct-95
03-May-96
03-Jul-98
12-Nov-10
11-Nov-94
11-Nov-94
11-Jun-95
12-Oct-95
26-Oct-95
03-May-96
03-Jul-98
12-Nov-10
10,000,000
20,670,000
580,000
31,250,000
62,500,000
15,000,000
420,000,000
560,000,000
Total Listed
Shares
10,000,000
30,670,000
31,250,000
62,500,000
125,000,000
140,000,000
560,000,000
1,120,000,000
Underwriter PT Wardley James Caple Indonesia
Stock Price, Frequency, Trading Days, Number and Value of Shares Traded and Market Capitalization
Month
January-13
February-13
March-13
April-13
May-13
June-13
July-13
August-13
September-13
October-13
November-13
December-13
January-14
February-14
March-14
April-14
May-14
June-14
Stock Price
High
Low
(Rp)
(Rp)
1,750
1,680
1,850
1,730
2,325
1,800
2,325
2,000
3,925
2,100
4,175
2,200
3,050
2,400
2,775
1,930
2,500
2,000
2,400
2,200
2,250
1,990
2,250
2,000
2,250
2,000
2,150
2,000
2,180
2,030
2,750
2,010
2,175
2,005
2,120
1,915
Shares Traded
Close
Volume
Value
(Rp) (Thousand Shares)
(Rp Million)
1,740
1,116.00
1,909.00
1,820
3,720.00
6,614.00
2,275
2,436.00
4,903.00
2,200
1,401.00
3,047.00
3,925
6,193.00
19,459.00
2,800
3,937.00
12,775.00
2,650
1,362.00
3,756.00
2,150
657.00
1,514.00
2,225
326.00
712.00
2,250
271.00
619.00
2,100
128.00
268.00
2,200
424.00
884.00
2,070
757.00
1,592.00
2,080
190.00
390.00
2,030
157.00
330.00
2,050
611.00
1,373.00
2,105
355.00
732.00
1,925
223.00
455.00
Trading
Listed
Market
Frequency
Day
Shares
201
572
350
251
1,614
1,843
408
156
107
69
47
67
137
95
94
373
264
111
21
20
18
21
21
19
22
17
17
17
13
17
19
15
17
19
18
16
1,120,000,000
1,120,000,000
1,120,000,000
1,120,000,000
1,120,000,000
1,120,000,000
1,120,000,000
1,120,000,000
1,120,000,000
1,120,000,000
1,120,000,000
1,120,000,000
1,120,000,000
1,120,000,000
1,120,000,000
1,120,000,000
1,120,000,000
1,120,000,000
Capitalization
(Rp Million)
1,948,800.00
2,038,400.00
2,548,000.00
2,464,000.00
4,396,000.00
3,136,000.00
296,800.00
2,408,000.00
2,492,000.00
2,520,000.00
2,352,000.00
2,464,000.00
2,318,400.00
2,329,600.00
2,273,600.00
2,296,000.00
2,357,600.00
2,156,000.00
Stock Price and Traded Chart
Thousand Shares
Stock Price (Rp)
4,500
800
4,000
700
3,500
600
3,000
500
2,500
400
2,000
300
1,500
200
1,000
100
500
-
Jan-13
Mar-13
May-13
Jul-13
Sep-13
Nov-13
Institute for Economic and Financial Research
http://digilib.mercubuana.ac.id/
Jan-14
Mar-14
May-14
481
PT Indofarma (Persero) Tbk.
Head Office/Factory
Commercial Office
Business
Company Status
Summary of Financial Statement
Jl. Indofarma No. 1
Cikarang Barat 17530, Jawa Barat
PO Box: 4111/Jkt 10041 Indonesia
Phone (021) 8832-3971, 8832-3975
Fax (021) 8832-3972/73
E-mail: general@indofarma.co.id
Website: www.indofarma.co.id
Jl. Tambak No. 2
Jakarta 13150
Phone (021) 8590-8350
Fax (021) 857-4503
Pharmaceutical
BUMN
(Million Rupiah)
2011
2012
2013
Financial Performance: The Company booked net income
amounted IDR54.223 billion in 2013, while last year booked
income worth IDR23.155 billion.
Brief History: Established on January 2 1996, the company dates back to 1918 when it was a pharmaceuticals factory
known as Pabrik Obat Manggarai. In 1942, ownership of this
pharmaceuticals factory changed hands from the Dutch to the
Japanese government.
In 1950, Pabrik Obat Manggarai was taken over by the
Indonesian government via the Department of Health, and became the pharmaceuticals production center for this government department. In 1979, the name of the factory changed to
the Department of Health Pharmaceuticals Production Center,
a nonprofit organization, whose primary task was to produce
essential medicines for public health care services. In 1981, the
name f this production center was changed to Indonesia Farma
(State Utility).
In anticipation of future growth and increased competition, in 1996, the status of this company was changed to a limited company, PT Indonesia Farma, or PT Indofarma for short.
That year the company also began expanding its local
distribution network. In 1996, the company acquired a 43.5%
shareholding in PT Riasima Abadi Farma, a producer of raw
materials used in the production of pharmaceuticals. In January 2000, the company set up subsidiary PT Indofarma Global
Medika, to deal with the distribution side of the company’s
business. In March 2000, the company acquired a 20% stake in
PT Asindo Husada Bhakti, which was set up to distribute pharmaceutical products through retail outlets.
In March 2001, the company made a public offering of its
shares.
Of the funds raised from this offering, 53% was used to
develop production capacity and facilities, and 43% to augment
working capital.
Shareholders
Government of Indonesia
Public
Pharmaceuticals
80.66%
19.34%
Total Assets
Current Assets
of which
Cash and cash equivalents
Time deposits
Trade receivables
Inventories
Non-Current Assets
of which
Fixed Assets-Net
Deffered Tax Assets
Investments
1,114,902
706,558
1,188,619
777,629
1,294,511
848,840
133,417
28
153,239
193,442
408,343
194,903
n.a
238,987
161,342
410,990
121,432
n.a
273,389
236,417
445,670
342,984
29,739
791
339,196
27,165
140
367,913
35,975
276
Liabilities
Current Liabilities
of which
Bank loans
Trade payables
Taxes payable
Accrued Expenses
Current maturities of
long-term debt
Non-Current Assets
505,708
459,404
538,517
369,864
703,717
670,903
75,848
289,874
12,352
70,358
75,955
247,767
6,740
34,335
199,154
304,641
2,206
41,750
4,951
46,304
255
168,653
163
32,815
Shareholders' Equity
Paid-up capital
Paid-up capital
in excess of par value
Retained earnings
609,194
309,927
650,102
309,927
590,793
309,927
75,100
224,167
75,100
265,075
75,100
205,766
1,203,467
807,283
396,184
304,226
91,959
(36,756)
55,203
36,970
1,156,050
788,155
367,896
284,587
83,309
(21,577)
61,732
42,385
1,337,498
999,930
337,568
369,874
(32,306)
(30,727)
(63,033)
(54,223)
12
197
n.a
163
14
210
1
330
(17)
191
n.a
153
13.66
0.83
n.a
n.a
24.13
1.57
0.10
0.00
(8.75)
0.80
n.a
n.a
1.54
0.83
0.45
7.64
3.07
1.57
1.08
3.32
6.07
2.10
0.83
0.45
7.21
3.67
1.76
0.97
3.57
6.52
1.27
1.19
0.54
(2.42)
(4.05)
1.56
1.03
(4.19)
(9.18)
Net Sales
Cost of Good Sold
Gross Profit
Operating Expenses
Operating Profit (Loss)
Other Income (Expenses)
Profit (Loss) before Taxes
Comprehensive Profit (Loss)
Per Share Data (Rp)
Earnings (Loss) per Share
Equity per Share
Dividend per Share
Closing Price
Financial Ratios
PER (x)
PBV (x)
Dividend Payout (%)
Dividend Yield (%)
Current Ratio (x)
Debt to Equity (x)
Leverage Ratio (x)
Operating Profit Margin (x)
Net Profit Margin (x)
Inventory Turnover (x)
Total Assets Turnover (x)
ROI (%)
ROE (%)
PER =-4,90x ; PBV = 0,92x (June 2014)
Financial Year: December 31
Public Accountant: Hendrawinata Eddy & Siddharta
482
Indonesian Capital Market Directory 2014
http://digilib.mercubuana.ac.id/
PT Indofarma (Persero) Tbk.
Pharmaceuticals
Board of Directors
President Director Arief Budiman
Directors Muhammad Umar, Syamsul Hadi
Board of Commissioners
President Commissioner Akmal Taher
Commissioners Rina Moreta, Fajar Rahmat Zulkarnaen
Number of Employees 1,883
No
Type of Listing
1
2
3
4
Negara RI (Seri A)
First Issue
Company Listing
Option Conversion
Listing Date
Trading Date
Number of Shares
per Listing
17-Apr-01
17-Apr-01
17-Apr-01
26-Aug-02
17-Apr-01
17-Apr-01
17-Apr-01
26-Aug-02
1
596,875,000
2,499,999,999
2,392,500
Total Listed
Shares
1
596,875,001
3,096,875,000
3,099,267,500
Underwriter
PT Bahana Securities
Stock Price, Frequency, Trading Days, Number and Value of Shares Traded and Market Capitalization
Trading
Listed
Market
Volume
Value
Frequency
Day
Shares
Capitalization
(Rp) (Thousand Shares)
350
310,631.00
340
190,078.00
315
246,199.00
295
267,121.00
310
274,865.00
260
93,228.00
200
91,381.00
168
80,020.00
170
60,780.00
176
114,482.00
163
20,257.00
153
18,069.00
164
40,259.00
172
34,989.00
196
101,260.00
185
70,489.00
182
248,078.00
168
16,591.00
(Rp Million)
104,787.00
64,487.00
81,157.00
84,710.00
87,373.00
25,462.00
21,909.00
14,320.00
11,104.00
20,770.00
3,403.00
3,688.00
7,217.00
6,042.00
18,874.00
13,626.00
4,571.00
2,965.00
8,982
5,477
8,076
16,071
7,826
2,983
5,052
5,181
4,664
5,495
1,481
1,075
3,945
2,797
6,020
3,753
1,999
1,250
21
20
19
22
22
19
23
17
21
21
20
19
20
20
20
20
18
21
3,099,267,500
3,099,267,500
3,099,267,500
3,099,267,500
3,099,267,500
3,099,267,500
3,099,267,500
3,099,267,500
3,099,267,500
3,099,267,500
3,099,267,500
3,099,267,500
3,099,267,500
3,099,267,500
3,099,267,500
3,099,267,500
3,099,267,500
3,099,267,500
(Rp Million)
1,084,744.00
1,053,751.00
976,269.00
914,284.00
960,773.00
805,810.00
619,854.00
520,677.00
526,875.00
545,471.00
505,181.00
474,188.00
508,280.00
533,074.00
607,456.00
573,364.00
564,067.00
520,677.00
Stock Price
Month
High
Low
January-13
February-13
March-13
April-13
May-13
June-13
July-13
August-13
September-13
October-13
November-13
December-13
January-14
February-14
March-14
April-14
May-14
June-14
(Rp)
370
355
345
340
345
310
265
215
195
192
179
175
174
181
202
202
192
186
(Rp)
290
315
305
280
260
245
200
145
158
168
159
152
151
161
164
180
179
166
Shares Traded
Close
Stock Price and Traded Chart
Stock Price (Rp)
Thousand Shares
400
30,000
350
25,000
300
20,000
250
200
15,000
150
10,000
100
5,000
50
-
Jan-13
Mar-13
May-13
Jul-13
Sep-13
Nov-13
Institute for Economic and Financial Research
http://digilib.mercubuana.ac.id/
Jan-14
Mar-14
May-14
483
PT Kalbe Farma Tbk.
Head Office
Factory
Business
Company Status
Pharmaceuticals
Summary of Financial Statement
KALBE Building
Jl. Letjend. Suprapto Kav. 4
Jakarta 10510
Phone (021) 4287-3888
Fax (021) 4287-3678
Website: www.kalbe.co.id
Kawasan Industri Delta Silicon
Jl. MH. Thamrin Blok A3-I
Lippo Cikarang, Bekasi 17550
Phone (021) 8990-7337, 8990-7333
Fax (021) 8990-7360
Pharmaceuticals
PMDN
(Million Rupiah)
2011
2012
2013
Financial Performance: Net income in 2011 increase to
IDR2.004 trillion compared to IDR1.772 trillion booked in
2012.
Brief History: Established in 1966, PT Kalbe Farma
Tbk. (“the Company” or “Kalbe”) has gone a long way from
its humble beginnings as a garage-operated pharmaceutical
business in North Jakarta. Throughout its more than 40-year
history, the Company has expanded by strategic acquisitions
of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform
itself into an integrated consumer health and nutrition enterprise with unrivalled innovation, marketing, branding, distribution, financial strength and R&D and production expertise
to promote its mission to improve health for a better life.
The Kalbe Group has an extensive and strong portfolio of brands
in the prescription pharmaceuticals, OTC pharmaceuticals, energy drink and nutrition products, complemented with a robust
packaging and distribution arm that reaches over 1 million outlets. The Company has succeeded in promoting its brands as the
undisputed market leaders not only in Indonesia but also in the
international markets, establishing such household names across
all healthcare and pharmaceutical segments as Promag, Mixagrip,
Woods, Komix, Prenagen and Extra Joss. Also, fostering and
expanding alliances with international partners have accelerated Kalbe’s advances in international markets and sophisticated
R&D ventures as well as the latest pharmaceutical and healthcare developments, including stem cell and cancer research.
The Group’s consolidation in 2005 has further enhanced production, marketing and financial capabilities, providing greater
leverage to widen local and international exposure. Today,
Kalbe is the largest publicly-listed pharmaceutical company in
Southeast Asia with over US$ 1 billion in market capitalization
and revenues of over Rp 7 trillion. Its cashrich position today
also provides for unlimited expansion opportunities in the future.
Shareholders
PT Gira Sole Prima
PT Santa Seha Sanadi
PT Diptanala Bahana
PT Lucasta Murni Cemerlang
PT Ladang Ira Panen
PT Bina Artha Charisma
Public
10.17%
9.70%
9.50%
9.47%
9.21%
8.66%
43.29%
Total Assets
Current Assets
of which
Cash and cash equivalents
Time deposits
Trade receivables
Inventories
Non-Current Assets
of which
Fixed Assets-Net
Deffered Tax Assets-Net
Investments
Other Assets
8,274,554
5,993,877
9,417,957
6,441,711
11,315,061
7,497,319
2,291,336
114,343
1,529,992
1,705,189
2,280,677
1,859,663
239,187
1,805,235
2,115,484
2,976,247
1,425,461
187,743
2,145,219
3,053,495
3,817,742
1,860,288
37,352
53,708
67,758
2,254,763
56,264
48,951
248,705
2,925,268
72,603
42,420
357,861
Liabilities
Current Liabilities
of which
Short-term debt
Trade payables
Accrued expenses
Taxes payable
Non-Current Liabilities
1,758,619
1,630,589
2,046,314
1,891,618
2,815,103
2,640,590
140,057
850,398
263,015
154,287
128,031
204,252
808,865
361,917
195,837
154,696
583,824
1,151,655
314,518
186,954
174,513
Shareholders' Equity
Paid-up capital
Paid-up capital
in excess of par value
Revaluation of fixed assets
Retained earnings (accumulated loss)
6,515,935
507,801
7,371,644
507,801
8,499,976
468,751
(32,318)
n.a
6,040,452
(32,318)
n.a
6,896,160
(34,119)
n.a
8,065,343
10,911,860
5,360,687
5,551,173
3,608,737
1,942,437
44,823
1,987,259
1,539,721
13,636,405
7,102,971
6,533,434
4,333,187
2,200,247
107,771
2,308,017
1,772,035
16,002,131
8,323,018
7,679,113
5,158,837
2,520,277
52,246
2,572,523
2,004,244
Per Share Data (Rp)
Earnings (Loss) per Share
Equity per Share
Dividend per Share
Closing Price
152
642
95
3,400
35
145
19
1,060
43
181
17
1,250
Financial Ratios
PER (x)
PBV (x)
Dividend Payout (%)
Dividend Yield (%)
22.43
5.30
62.66
14.81
30.38
7.30
54.45
13.09
29.23
6.89
39.76
9.38
Current Ratio (x)
Debt to Equity (x)
Leverage Ratio (x)
Gross Profit Margin (x)
Operating Profit Margin (x)
Net Profit Margin (x)
Inventory Turnover (x)
Total Assets Turnover (x)
ROI (%)
ROE (%)
3.68
0.27
0.21
0.51
0.18
0.14
3.14
1.32
18.61
23.63
3.41
0.28
0.22
0.48
0.16
0.13
3.36
1.45
18.82
24.04
2.84
0.33
0.25
0.48
0.16
0.13
2.73
1.41
17.71
23.58
Net Sales
Cost of Goods Sold
Gross Profit
Operating Expenses
Operating Profit
Other Income (Expenses)
Profit (Loss) before Taxes
Comprehensive Profit (Loss)
PER = 40,13x ; PBV = 9,14x (June 2014)
Financial Year: December 31
Public Accountant: Purwantono, Suherman & Surja
486
Indonesian Capital Market Directory 2014
http://digilib.mercubuana.ac.id/
PT Kalbe Farma Tbk.
Pharmaceuticals
Board of Commissioners
President Commissioner Drs. Johannes Setijono
Commissioners Santoso Oen, BA, Ferdinand Aryanto,
Jozef Darmawan Angkasa, Farid A. Moeloek,
Lucky Surjadi Slamet
No
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Type of Listing
First Issue
Partial Listing
Cooperative
Company Listing
Bonus Shares
Right Issue
Bonus Shares
Dividend Shares
Stock Split
Stock Split
Bonus Shares
Stock Split
Additional Listing (Merger)
Stock Split
Decrease in Issued Shares
Board of Directors
President Director
Bernadette Ruth Irawati Setiady
Directors Budi Dharma Wireksoatmodjo, Vidjongtius,
Ongkie Tedjasurja, Bujung Nugroho
Number of Employees
11,351
Listing Date
Trading Date
Number of Shares
per Listing
1991
1991
1992
1992
1992
1993
1994
1994
1996
1999
2000
2-Jan-04
21-Dec-05
8-Oct-12
13-Dec-13
1991
1992
1999
1992
1992
1993
1994
1994
1996
1999
2000
2-Jan-04
21-Dec-05
8-Oct-12
13-Dec-13
10,000,000
10,000,000
500,000
29,500,000
50,000,000
8,000,000
75,600,000
32,400,000
216,000,000
1,728,000,000
1,900,800,000
4,060,800,000
2,034,414,422
40,624,057,688
-3,904,950,000
Total Listed
Shares
10,000,000
20,000,000
20,500,000
50,000,000
100,000,000
108,000,000
183,600,000
216,000,000
432,000,000
2,160,000,000
4,060,800,000
8,121,600,000
10,156,014,422
50,780,072,110
46,875,122,110
Underwriters PT Ing Barings Securities, PT Merincorp
Stock Price, Frequency, Trading Days, Number and Value of Shares Traded and Market Capitalization
Month
January-13
February-13
March-13
April-13
May-13
June-13
July-13
August-13
September-13
October-13
November-13
December-13
January-14
February-14
March-14
April-14
May-14
June-14
Stock Price
High
Low
(Rp)
(Rp)
1,130
1,000
1,300
1,070
1,380
1,190
1,390
1,200
1,560
1,320
1,450
1,130
1,500
1,300
1,510
1,110
1,440
1,180
1,390
1,220
1,370
1,200
1,260
1,160
1,455
1,260
1,480
1,360
1,495
1,400
1,550
1,455
1,660
1,535
1,670
1,560
Close
(Rp)
1,090
1,290
1,240
1,390
1,450
1,440
1,430
1,350
1,180
1,300
1,220
1,250
1,405
1,450
1,465
1,545
1,540
1,660
Shares Traded
Volume
Value
(Thousand Shares)
(Rp Million)
1,891,111.00
1,965,394.00
1,682,306.00
1,946,563.00
1,724,553.00
2,181,688.00
1,928,884.00
2,479,590.00
1,973,262.00
2,887,922.00
1,752,293.00
2,311,851.00
1,558,750.00
2,191,524.00
1,391,354.00
1,888,689.00
1,885,390.00
2,494,405.00
1,732,152.00
2,302,731.00
1,256,613.00
1,624,072.00
1,220,791.00
1,480,756.00
1,481,958.00
2,036,864.00
1,393,045.00
1,969,357.00
1,431,485.00
2,067,755.00
1,213,480.00
1,838,928.00
933,943.00
1,482,209.00
726,980.00
1,181,149.00
Trading
Listed
Market
Frequency
Day
Shares
48,914
69,492
51,451
51,858
67,894
76,854
100,827
71,639
92,703
82,161
55,361
54,113
115,285
90,285
100,433
90,527
54,597
94,173
21
20
19
22
22
19
23
17
21
21
20
19
20
20
20
20
18
21
50,780,072,110
50,780,072,110
50,780,072,110
50,780,072,110
50,780,072,110
50,780,072,110
50,780,072,110
50,780,072,110
50,780,072,110
50,780,072,110
50,780,072,110
46,875,122,110
46,875,122,110
46,875,122,110
46,875,122,110
46,875,122,110
46,875,122,110
46,875,122,110
Capitalization
(Rp Million)
55,350,279.00
65,506,293.00
62,967,289.00
70,584,300.00
73,631,105.00
73,123,304.00
72,615,503.00
68,553,097.00
59,920,485.00
66,014,094.00
61,951,688.00
58,593,903.00
65,859,547.00
67,968,927.00
68,672,054.00
72,422,064.00
72,187,688.00
77,812,703.00
Stock Price and Traded Chart
Stock Price (Rp)
Thousand Shares
1,800
180,000
1,600
160,000
1,400
140,000
1,200
120,000
1,000
100,000
800
80,000
600
60,000
400
40,000
200
20,000
-
Jan-13
Mar-13
May-13
Jul-13
Sep-13
Nov-13
Institute for Economic and Financial Research
http://digilib.mercubuana.ac.id/
Jan-14
Mar-14
May-14
487
PT Kimia Farma (Persero) Tbk.
Head Office
Factories
Business
Company Status
Jl. Veteran No. 9, Jakarta 10110
Phone (021) 384-7709, 345-7708
Fax (021) 381-4441, 345-4338-9
Email: ipo@kimiafarma.co.id
Website: http://www.kimiafarma.co.id
- Jl. Rawagelam V No. 1, Kawasan Industri
Pulogadung, Jakarta 13930
Phone (021) 460-9354, Fax (021) 460-3143
- Jl. Simongan PO. BOX 1206, Semarang 50147
Phone (024) 760-4060, Fax (024) 760-5265
- Jl. Padjajaran No. 29-31, Bandung 40171
Phone (022) 420-4043, Fax (022) 423-7079
- Ds. Jombok, Kec. Kesamben, Kab. Jombang
PO. BOX 126 Mojokerto 61301
Phone (0321) 397-300/2, Fax (0321) 397-303
- Jl. Raya Medan-Tanjung Morawa Km. 9
Medan 20148
Phone (061) 786-7022, Fax (061) 786-5744
Pharmacy
BUMN
Financial Performance: The Company recorded net
income in 2013 at IDR215.642 billion, or increased from
IDR205.764 billion recorded in 2012.
Brief History: Kimia Farma is a pioneer in the pharmaceutical industry of Indonesia. Ancestor will the company can be traced back to 1917, when NV Chemicalen
Handle Rathkamp & Co.., The first pharmaceutical company in
the East Indies, established.
In line with the policy of nationalization of the company exDutch company, in 1958 the government merged several pharmaceutical companies into PNF Bhinneka Kimia Farma. Next on
dated August 16, 1971 the Company converted its legal form
Limited, a PT Kimia Farma (Persero). Since July 4, 2001 Kimia
Farma as a public company listed on the Jakarta Stock Exchange
and Surabaya Stock Exchange.
Shareholders
Government of Indonesia
Public
90.03%
9.97%
Pharmaceuticals
Summary of Financial Statement
(Million Rupiah)
2011
2012
2013
Total Assets
Current Assets
of which
Cash and cash equivalents
Trade receivables
Inventories
Non-Current Assets
of which
Fixed Assets-Net
Deffered Tax Assets-Net
Investment
Other Assets
1,794,242
1,263,030
2,076,348
1,505,798
2,471,940
1,810,615
199,386
384,037
456,069
531,213
316,498
458,729
530,417
570,549
394,150
546,576
640,909
661,325
426,720
35,360
419
54,201
449,140
38,356
922
68,285
498,644
39,283
381
109,147
541,737
459,694
634,814
537,184
847,585
746,123
14,389
284,234
44,306
82,042
17,377
341,133
46,608
97,630
47,376
477,892
52,709
101,462
Shareholders' Equity
Paid-up capital
Paid-up capital
in excess of par value
Retained earnings
1,252,506
555,400
1,441,534
555,400
1,624,355
555,400
43,580
653,526
43,580
842,554
43,580
1,025,375
Net Sales
Cost of Good Sold
Gross Profit
Operating Expenses
Operating Profit
Other Income (Expenses)
Profit (loss) before Taxes
Comprehensive Profit (loss)
3,481,166
2,443,150
1,038,016
793,950
244,066
(12,059)
232,007
171,763
3,734,241
2,559,074
1,175,167
890,010
285,157
(6,872)
278,284
205,764
4,348,074
3,055,922
1,292,152
998,387
293,765
(9,640)
284,125
215,642
Per Share Data (Rp)
Earnings per Share
Equity per Share
Dividend per Share
Closing Price
31
226
n.a
340
37
260
6
740
39
292
n.a
590
Financial Ratios
PER (x)
PBV (x)
Dividend Payout (%)
Dividend Yield (%)
10.99
1.51
n.a
n.a
19.97
2.85
0.15
0.01
15.20
2.02
n.a
n.a
Current Ratio (x)
Debt to Equity (x)
Leverage Ratio (x)
Operating Profit Margin (x)
Net Profit Margin (x)
Inventory Turnover (x)
Total Assets Turnover (x)
ROI (%)
ROE (%)
2.75
0.43
0.30
0.07
0.05
1.74
1.94
9.57
13.71
2.80
0.44
0.31
0.08
0.06
1.68
1.80
9.91
14.27
2.43
0.52
0.34
0.07
0.05
1.56
1.76
8.72
13.28
Liabilities
Current Liabilities
of which
Bank loans
Trade payables
Taxes payable
Non-Current Liabilities
PER = 45,25x ; PBV = 3,89x (June 2014)
Financial Year: December 31
Public Accountant: HandrawinataEddy & Siddharta
488
Indonesian Capital Market Directory 2014
http://digilib.mercubuana.ac.id/
PT Kimia Farma (Persero) Tbk.
Pharmaceuticals
Board of Commissioners
President Commissioner dr. Ratna Rosita, MPHM
Commissioners Letjend. (Purn.) Effendi Rangkuti, SH,
dr. H. Darmansyah,
Dr. Ir. Upik Rosalina Wasrin, DEA,
Prof. Dr. Wahono Sumaryono
No
Type of Listing
1
2
3
First Issue
Company Listing
Negara RI (Seri A)
Board of Directors
President Director Drs. Rusdi Rosman, MBA
Directors Drs. Jisman Siagian, Wahyuli Safari,
Farida Astuti, Pujianto
Number of Employees 5,413
Listing Date
Trading Date
Number of Shares
per Listing
04-Jul-01
04-Jul-01
04-Jul-01
04-Jul-01
04-Jul-01
04-Jul-01
500,000,000
5,053,999,999
1
Total Listed
Shares
500,000,001
5,554,000,000
5,554,000,001
Underwriter
PT Danareksa Sekuritas
Stock Price, Frequency, Trading Days, Number and Value of Shares Traded and Market Capitalization
Month
January-13
February-13
March-13
April-13
May-13
June-13
July-13
August-13
September-13
October-13
November-13
December-13
January-14
February-14
March-14
April-14
May-14
June-14
Stock Price
High
Low
(Rp)
(Rp)
1,050
710
1,140
970
1,160
1,030
1,090
960
1,040
890
980
840
910
790
810
460
670
420
720
520
640
480
590
495
745
580
795
685
925
715
945
830
1,055
890
1,090
940
Close
(Rp)
1,030
1,090
1,080
990
960
890
790
495
550
630
510
590
690
750
900
915
1,050
990
Shares Traded
Volume
Value
(Thousand Shares)
(Rp Million)
243,219.00
215,537.00
182,628.00
191,795.00
209,173.00
228,569.00
101,967.00
103,706.00
123,350.00
119,536.00
53,319.00
48,463.00
32,511.00
27,785.00
76,785.00
41,254.00
96,833.00
54,238.00
68,632.00
43,138.00
47,183.00
26,577.00
68,407.00
37,057.00
133,610.00
92,483.00
123,927.00
93,268.00
140,408.00
112,215.00
72,488.00
64,877.00
119,535.00
116,739.00
71,768.00
72,749.00
Trading
Listed
Market
Frequency
Day
Shares
7,774
8,270
13,458
6,031
7,163
4,135
2,562
9,487
5,806
3,866
3,281
2,734
11,212
9,404
10,884
7,572
10,210
8,412
21
20
19
22
22
19
23
17
21
21
20
19
20
20
20
20
18
21
5,554,000,001
5,554,000,001
5,554,000,001
5,554,000,001
5,554,000,001
5,554,000,001
5,554,000,001
5,554,000,001
5,554,000,001
5,554,000,001
5,554,000,001
5,554,000,001
5,554,000,001
5,554,000,001
5,554,000,001
5,554,000,001
5,554,000,001
5,554,000,001
Capitalization
(Rp Million)
5,720,620.00
6,053,860.00
5,998,320.00
5,498,460.00
5,331,840.00
4,943,060.00
4,387,660.00
2,749,230.00
3,054,700.00
3,499,020.00
2,832,540.00
3,276,860.00
3,832,260.00
4,165,500.00
4,998,600.00
5,081,910.00
5,831,700.00
5,498,460.00
Stock Price and Traded Chart
Thousand Shares
Stock Price (Rp)
1,200
40,000
35,000
1,000
30,000
800
25,000
600
20,000
15,000
400
10,000
200
5,000
-
Jan-13
Mar-13
May-13
Jul-13
Sep-13
Nov-13
Institute for Economic and Financial Research
http://digilib.mercubuana.ac.id/
Jan-14
Mar-14
May-14
489
PT Merck Tbk.
(Formerly PT Merck Indonesia Tbk)
Head Office
Factory
Business
Company Status
Jl. T.B. Simatupang No. 8
Pasar Rebo, Jakarta 13760
Phone (021) 840-0081, 8779-1415, 2856-5600
Fax (021) 840-0492, 2856-5601
Website: www.merck.co.id
Jl. T.B. Simatupang No. 8
Pasar Rebo, Jakarta 13760
Phone (021) 840-0081, 8779-1415
Fax (021) 840-0492
Industry and Trader Pharmaceuticals
PMA
Financial Performance: The Company booked net income
amounted IDR175 billion in 2013, increase from IDR107 billion
booked in last year.
Brief History: Initiated by E. Merck, Darmstadt, Germany,
the company was incorporated on 14th October 1970. The
setting up of a manufacturing plant for pharmaceutical products
in Jakarta in 1972 gave the company a strong base for development in Indonesia.
The company started its commercial production in 1974.
A basic raw material plant, producing Thiamine Disulfide (vitamin B1), was inaugurated in 1983. Manufacturing, packaging,
quality control, and warehousing facilities for the pharmaceutical production were expanded in 1985. Products of the company are mostly for the local market, but since 1987 exports
were made to Malaysia,
Singapore, Thailand, and Germany. In fulfillment of an
obligation to divest 30% of the company’s capital to Indonesia
investor, the company through the Jakarta Stock Exchange,
went public with 1,680,000 shares in July 1981. The company
conducted a limited public offering I in May 1999 in order to
strengthen its capital structure. This was achieved by settling
all long term loans in foreign currency as well as expanding the
company’s business.
In April 1999 there was a global merger between Astra
AB and Zeneca Group PLC, as a result of which a new company,
Astra Zeneca PLC, was established. Since this new company is
represented in Indonesia, hence the whole Astra Division within the company, its employees as well as the marketing business
of Astra products, have been wholely absorbed by PT Zeneca
Pharma Indonesia at the end of August 1999.
Shareholders
Merck Holding GmbH, Germany
Emedia Export Company mbH, Germany
Public
73.99%
12,66%
13.35%
Pharmaceuticals
Summary of Financial Statement
(Million Rupiah)
2011
2012
2013
Total Assets
Current Assets
of which
Cash and cash equivalents
Trade receivables
Inventories
Non-Current Assets
of which
Fixed Assets-Net
Deffered Tax Assets
Other Assets
Liabilities
Current Liabilities
of which
Trade payables
Taxes payable
Non-Current Liabilities
584,389
491,726
569,431
463,883
696,946
588,238
253,731
106,605
123,559
92,663
143,552
67,305
237,577
105,548
184,227
136,436
249,319
108,709
61,536
10,759
2,355
63,318
11,824
3,611
61,627
15,507
1,755
90,207
65,431
152,689
119,828
184,728
147,818
16,295
13,926
24,776
62,401
6,987
32,861
73,931
12,327
36,909
Shareholders' Equity
Paid-up capital
Paid-up capital
in excess of par value
Revaluation of fixed assets
Retained earnings
494,182
22,400
416,742
22,400
512,219
22,400
17,562
n.a
454,220
17,562
n.a
376,780
17,562
n.a
472,257
Net Sales
Cost of Goods Sold
Gross Profit
Operating Expenses
Operating Profit
Other Income (Expenses)
Profit before Taxes
Comprehensive Profit
918,532
436,394
482,138
283,556
198,582
84,645
283,227
231,159
929,877
505,435
424,442
282,602
141,840
4,075
145,915
107,808
1,193,952
648,473
545,480
63,432
482,047
(247,339)
234,708
175,445
Per Share Data (Rp)
Earnings per Share
Equity per Share
Dividend per Share
Closing Price
10,320
22,062
8
132,500
4,813
18,605
4
152,000
7,832
22,867
6
189,000
Financial Ratios
PER (x)
PBV (x)
Dividend Payout (%)
Dividend Yield (%)
12.84
6.01
0.08
0.01
31.58
8.17
0.07
0.00
24.13
8.27
0.08
0.00
Current Ratio (x)
Debt to Equity (x)
Leverage Ratio (x)
Gross Profit Margin (x)
Operating Profit Margin (x)
Net Profit Margin (x)
Inventory Turnover (x)
Total Assets Turnover (x)
ROI (%)
ROE (%)
7.52
0.18
0.15
0.52
0.22
0.25
3.53
1.57
39.56
46.78
3.87
0.37
0.27
0.46
0.15
0.12
2.13
1.63
18.93
25.87
3.98
0.36
0.27
0.46
0.40
0.15
2.60
1.71
25.17
34.25
PER = 47,68x ; PBV = 8,03x (June 2014)
Financial Year: December 31
Public Accountant: KPMG Siddharta Siddharta & Widjaja
490
Indonesian Capital Market Directory 2014
http://digilib.mercubuana.ac.id/
PT Merck Tbk.
(Formerly PT Merck Indonesia Tbk)
Pharmaceuticals
Board of Commissioners
President Commissioner Peter Ulrich Mannheimer
Commissioners Hon Keong Choo, Parulian Simanjuntak
Board of Directors
President Director Martin Feulner
Directors Bambang Nurcahyo, Dra. Elly Megawati Asali,
Holger Guenzel, Evie Yulin
Number of Employees 767
No
Type of Listing
1
2
3
First Issue
Riight Issue
Company Listing
Listing Date
Trading Date
Number of Shares
per Listing
23-Jul-81
19-May-99
22-Dec-00
23-Jul-81
19-May-99
22-Dec-00
1,680,000
16,800,000
3,920,000
Total Listed
Shares
1,680,000
18,480,000
22,400,000
Underwriters
PT ASEAM Indonesia, PT Danareksa Sekuritas, PT Multi Finance Corporation
Stock Price, Frequency, Trading Days, Number and Value of Shares Traded and Market Capitalization
Month
January-13
February-13
March-13
April-13
May-13
June-13
July-13
August-13
September-13
October-13
November-13
December-13
January-14
February-14
March-14
April-14
May-14
June-14
Stock Price
High
Low
(Rp)
(Rp)
152,000 152,000
152,000 152,000
152,000 150,000
0
0
235,500 145,000
225,000 210,000
215,000 151,500
215,000 200,000
0
0
180,000 170,000
182,000 170,000
189,000 170,000
189,000 189,000
0
0
207,000 190,000
200,000 200,000
199,950 175,000
194,000 194,000
Shares Traded
Close
Volume
Value
(Rp) (Thousand Shares)
(Rp Million)
152,000
0.50
76.00
152,000
5.00
685.00
152,000
2.00
303.00
152
0.00
0.46
233,500
70.00
14,586.00
210,000
8.00
1,556.00
210,000
24.00
4,585.00
215,000
3.00
628.00
215,000
0.00
0.00
170,000
34.00
5,890.00
178,000
20.00
3,413.00
189,000
6.00
1,077.00
189,000
0.10
19.00
189,000
0.00
0.00
199,950
90.00
17,206.00
200,000
74.00
13,220.00
175,000
3.00
609.00
194,000
0.10
19.00
Trading
Listed
Market
Frequency
Day
Shares
1
7
3
1
96
8
34
7
0
45
27
11
1
0
51
11
10
1
1
4
3
1
15
3
9
4
0
6
6
5
1
0
13
6
5
1
22,400,000
22,400,000
22,400,000
22,400,000
22,400,000
22,400,000
22,400,000
22,400,000
22,400,000
22,400,000
22,400,000
22,400,000
22,400,000
22,400,000
22,400,000
22,400,000
22,400,000
22,400,000
Capitalization
(Rp Million)
3,404,800.00
3,404,800.00
3,404,800.00
3,404,800.00
5,230,400.00
4,704,000.00
4,704,000.00
4,816,000.00
4,816,000.00
3,808,000.00
3,987,200.00
4,233,600.00
4,233,600.00
4,233,600.00
4,478,880.00
4,480,000.00
3,920,000.00
4,345,600.00
Stock Price and Traded Chart
Stock Price (Rp)
Thousand Shares
250,000
1
1
200,000
0
150,000
0
100,000
0
50,000
0
-
Jan-13
Mar-13
May-13
Jul-13
Sep-13
Nov-13
Institute for Economic and Financial Research
http://digilib.mercubuana.ac.id/
Jan-14
Mar-14
May-14
491
PT Pyridam Farma Tbk.
Head Office
Factory
Business
Company Status
Pharmaceuticals
Summary of Financial Statement
Jl. Kemandoran VIII No. 16
Jakarta 12210
Phone (021) 530-7551-52
Fax (021) 532-9049
E-mail: info@pyridam.com
Website: www.pyridam.com
Jl. Hanjawar
Pacet , Cianjur 43253, Jawa Barat
Phone (0263) 580-833, 580-855
Fax (0263) 582-290
E-mail: info@pyridam.com
Pharmaceuticals
PMDN
(Million Rupiah)
2011
2012
2013
Total Assets
Current Assets
of which
Cash and cash equivalents
Trade receivables
Inventories
Non-Current Assets
of which
Fixed Assets-Net
Deffered Tax Assets-Net
Financial Performance: The Company booked net income
amounted IDR6.196 billion in 2013, higher than last year income worth IDR5.308 billion.
Brief History: Pyridam was established in 1976 by Mr.
Sarkri Kosasih, a well-known person in pharmaceutical industry
by then. The name Pyridam was inspired by the phenomena of
Pyramids - one of the oldest Wonders oh the World. Pyridam
started by distributing veterinary medicines. Shortly, Pyridam
began manufacturing its own-formulation animal health products, and a three-story factory building was built. It worked
very closely to help farmers to develop advanced animal husbandry for that time. The work received recognition from the
government, and Pyridam was awarded the title “Partner with
Good Performance” in 1994 by the Ministry of Agriculture.
In 1985, Pyridam established its Pharmaceutical Division,
which develop quickly. Accelerated improvement enabled Pyridam to build a brand new production plant on 35,000 sqm land
in Cianjur, West Java, with state of the art design, machinery,
and environmental management. The plant started its operation in April 2001. In late 2000, the management leadership was
passed from Mr. Sarkri Kosasih to Mr. Handoko Boedi Soetrisno. Under new leadership, Pyridam opened up its ownership to
the public, which proves that Pyridam complies with the overall
conditions of a healthy and professional company.
118,034
61,889
135,850
68,588
175,119
74,974
4,521
24,058
29,523
56,144
5,343
30,568
25,047
67,262
7,567
30,274
35,867
100,145
55,114
1,001
66,154
1,042
97,554
2,510
Liabilities
Current Liabilities
of which
Bank loans
Trade payables
Taxes payable
Accrued expenses
Non-Current Liabilities
35,636
24,367
48,144
28,420
81,218
48,786
12,573
2,542
2,886
3,859
11,270
14,816
1,191
3,801
697
19,724
23,370
7,088
3,385
3,369
32,432
Shareholders' Equity
Paid-up capital
Paid-up capital
in excess of par value
Retained earnings (accumulated loss)
82,397
53,508
87,705
53,508
93,901
53,508
2,065
26,824
2,065
32,132
2,065
38,328
151,094
49,501
101,593
94,588
7,005
81
7,085
5,172
176,731
61,056
115,675
106,777
8,898
(926)
7,972
5,308
192,556
62,125
130,430
120,703
9,727
(1,227)
8,500
6,196
10
154
n.a
176
10
164
n.a
177
12
175
n.a
147
18.21
1.14
n.a
n.a
17.84
1.08
n.a
n.a
12.70
0.84
n.a
n.a
2.54
0.43
0.30
0.67
0.05
0.03
1.68
1.28
4.38
6.28
2.41
0.55
0.35
0.65
0.05
0.03
2.44
1.30
3.91
6.05
1.54
0.86
0.46
0.68
0.05
0.03
1.73
1.10
3.54
6.60
Net Sales
Cost of Goods Sold
Gross Profit
Operating Expenses
Operating Profit (Loss)
Other Income (Expenses)
Profit (Loss) before Taxes
Comprehensive Profit (Loss)
Per Share Data (Rp)
Earnings (Loss) per Share
Equity per Share
Dividend per Share
Closing Price
Financial Ratios
PER (x)
PBV (x)
Dividend Payout (%)
Dividend Yield (%)
Shareholders
PT Pyridam Internasional Corporation
Ir. Sarkri Kosasih
Rani Tjandra
Public
Current Ratio (x)
Debt to Equity (x)
Leverage Ratio (x)
Gross Profit Margin (x)
Operating Profit Margin (x)
Net Profit Margin (x)
Inventory Turnover (x)
Total Assets Turnover (x)
ROI (%)
ROE (%)
53.85%
11.54%
11.54%
23.07%
PER = 68,19x ; PBV = 0,75x (June 2014)
Financial Year: December 31
Public Accountant: Tanubrata Sutanto Fahmi & Rekan
494
Indonesian Capital Market Directory 2014
http://digilib.mercubuana.ac.id/
PT Pyridam Farma Tbk.
Pharmaceuticals
Board of Directors
President Director Michael Handoko Boedi Soetrisno
Directors Indrawati Kosasih, Andreas Herman Oslan
Board of Commissioners
President Commissioner Ir. Sarkri Kosasih
Commissioners Lindia Kosasih, Dra. Lianny Suraja
Number of Employees 773
No
Type of Listing
1
2
3
First Issue
Company Listing
Stock Dividend
Listing Date
Trading Date
Number of Shares
per Listing
16-Oct-01
16-Oct-01
21-Nov-02
16-Oct-01
27-May-02
21-Nov-02
120,000,000
400,000,000
15,080,000
Total Listed
Shares
120,000,000
520,000,000
535,080,000
Underwriters
PT Trimegah Securities Tbk, PT Kresna Graha Sekurindo Tbk
Stock Price, Frequency, Trading Days, Number and Value of Shares Traded and Market Capitalization
Month
January-13
February-13
March-13
April-13
May-13
June-13
July-13
August-13
September-13
October-13
November-13
December-13
January-14
February-14
March-14
April-14
May-14
June-14
Stock Price
High
Low
(Rp)
(Rp)
187
172
183
171
225
172
230
184
200
180
183
158
178
147
158
120
172
130
156
135
155
142
151
143
150
141
153
144
168
144
151
138
143
132
137
129
Close
(Rp)
180
179
200
196
180
166
155
152
135
149
148
147
147
151
146
140
139
133
Shares Traded
Volume
Value
(Thousand Shares)
(Rp Million)
5,701.00
1,026.00
2,008.00
349.00
107,099.00
21,777.00
242,077.00
51,830.00
108,859.00
21,003.00
5,909.00
996.00
25,084.00
4,199.00
11,298.00
1,621.00
124,142.00
19,992.00
16,480.00
2,379.00
7,008.00
1,045.00
1,243.00
183.00
864.00
127.00
2,662.00
397.00
39,714.00
6,329.00
3,717.00
529.00
2,090.00
288.00
1,680.00
225.00
Trading
Listed
Market
Frequency
Day
Shares
684
315
15,317
28,664
17,653
492
3,704
1,880
17,654
2,296
672
137
243
360
6,911
617
542
354
21
18
19
22
22
19
23
17
21
21
19
17
19
20
20
20
18
20
535,080,000
535,080,000
535,080,000
535,080,000
535,080,000
535,080,000
535,080,000
535,080,000
535,080,000
535,080,000
535,080,000
535,080,000
535,080,000
535,080,000
535,080,000
535,080,000
535,080,000
535,080,000
Capitalization
(Rp Million)
96,314.00
95,779.00
107,016.00
104,876.00
96,314.00
88,823.00
82,937.00
81,332.00
72,236.00
79,727.00
79,192.00
78,657.00
78,657.00
80,797.00
78,122.00
74,911.00
74,376.00
71,168.00
Stock Price and Traded Chart
Thousand Shares
Stock Price (Rp)
12,000
250
10,000
200
8,000
150
6,000
100
4,000
50
2,000
-
Jan-13
Mar-13
May-13
Jul-13
Sep-13
Nov-13
Institute for Economic and Financial Research
http://digilib.mercubuana.ac.id/
Jan-14
Mar-14
May-14
495